A
72.92
0.00 (-0.01%)
| Penutupan Terdahulu | 72.92 |
| Buka | 73.00 |
| Jumlah Dagangan | 1,064,021 |
| Purata Dagangan (3B) | 2,208,078 |
| Modal Pasaran | 11,263,826,944 |
| Harga / Jualan (P/S) | 459.10 |
| Harga / Buku (P/B) | 5.97 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -8,360.90% |
| EPS Cair (TTM) | -3.00 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -55.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.45% |
| Nisbah Semasa (MRQ) | 16.91 |
| Aliran Tunai Operasi (OCF TTM) | -355.32 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -245.73 M |
| Pulangan Atas Aset (ROA TTM) | -22.47% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.19% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Avidity Biosciences, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.38 |
|
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 5.17% |
| % Dimiliki oleh Institusi | 112.41% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Janus Henderson Group Plc | 30 Sep 2025 | 14,522,915 |
| Rtw Investments, Lp | 30 Sep 2025 | 11,372,829 |
| Wellington Management Group Llp | 30 Sep 2025 | 10,065,187 |
| Price T Rowe Associates Inc /Md/ | 30 Sep 2025 | 9,787,417 |
| Ra Capital Management, L.P. | 30 Sep 2025 | 8,641,031 |
| Avoro Capital Advisors Llc | 30 Sep 2025 | 7,645,000 |
| Polar Capital Holdings Plc | 30 Sep 2025 | 2,796,760 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 02 Feb 2026 | Pengumuman | Avidity Biosciences Announces Expected Record Date for Spin-Off |
| 19 Nov 2025 | Pengumuman | Avidity Biosciences Announces U.S. Managed Access Program (MAP) for Investigational Therapy del-zota in DMD44 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |